Two Japanese Generic Drugs Found To Deviate From Standards
This article was originally published in PharmAsia News
Two generic drugs used in Japan were found to have deviated from specified standard and have been recalled, according to the annual generic drug quality assurance survey conducted by Japan's Ministry of Health, Labor and Welfare in 2008. The two products, Nippro's cilostazol and Isei's nifedipine were found to have different standards than specified by their manufacturing and marketing approvals. Both makers have since voluntarily recalled the products. The Ministry said no adverse effects were reported. A total of 876 generic products marketed in Japan were tested in the last year. (Click here for more - Japanese language
You may also be interested in...
Amarin had argued that Vascepa’s sales success showed that its patents were not obvious, but the court found otherwise, even as it concluded that Hikma, Dr. Reddy's and West-Ward has infringed on the fish oil pill's patents.
FTC pursuing bogus health and other products or services capitalizing on Covid-19 fear with scams skyrocketing. However, FTC says its enforcement will consider whether businesses are making good faith efforts to produce products in high demand.
Warning letters show FDA's coronavirus investigations inthe consumer health marketplace didn't stop when it suspended facility inspections. The letters identify firms that previously marketed only bedding products as offering supplements with coronavirus claims or that are in other countries and are shipping to US consumers products promoted with coronavirus claims.